Exscientia (NASDAQ:EXAI) Trading Up 5.7%

Exscientia plc (NASDAQ:EXAI)’s share price rose 5.7% during mid-day trading on Monday . The stock traded as high as $4.35 and last traded at $4.26. Approximately 57,492 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 687,346 shares. The stock had previously closed at $4.03.

Analyst Ratings Changes

EXAI has been the subject of several recent analyst reports. Bank of America cut shares of Exscientia from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $11.00 to $9.00 in a report on Friday, January 5th. Morgan Stanley reissued an “equal weight” rating and set a $7.00 price objective on shares of Exscientia in a report on Monday, April 22nd.

Exscientia Price Performance

The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average price is $5.53 and its two-hundred day moving average price is $5.83.

Exscientia (NASDAQ:EXAI) last announced its earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $41.63 million. As a group, research analysts predict that Exscientia plc will post -1.76 EPS for the current fiscal year.

Institutional Trading of Exscientia

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its position in shares of Exscientia by 76.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company’s stock valued at $53,000 after buying an additional 4,029 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after purchasing an additional 2,302 shares in the last quarter. Walled Lake Planning & Wealth Management LLC purchased a new position in Exscientia during the fourth quarter valued at approximately $64,000. New Republic Capital LLC bought a new position in shares of Exscientia in the fourth quarter worth approximately $128,000. Finally, Jump Financial LLC increased its stake in shares of Exscientia by 47.7% in the fourth quarter. Jump Financial LLC now owns 53,755 shares of the company’s stock worth $345,000 after purchasing an additional 17,355 shares in the last quarter. Hedge funds and other institutional investors own 41.58% of the company’s stock.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.